Literature DB >> 1485748

[Polyposis of the nasal sinuses. Epidemiology and clinical aspects of 350 cases. Treatment and results with a follow-up over 5 years on 93 cases].

J J Braun1, F Haas, C Conraux.   

Abstract

The authors report a series of 350 patients referred for clinical investigation of nasal polyps between 1980 and 1990. 93 patients were followed for more than 5 years. Allergy to inhalants was rarely found (2.8%). Detailed study of past rhinosinusal and bronchial symptoms often revealed a history of vasomotor rhinitis (nasal hyperreactivity HRN) preceding the nasal polyposis by a mean interval of 8 years. The ratio non-allergic vasomotor rhinitis/nasal polyps was 4.31 in women (41.4% of the patients) and 1.74 in men (58.6% of the patients). Treatment is usually based on the use of local corticosteroids. However, because of the variable clinical pattern of nasal polyposis treatment may be medical alone or both medical and surgical, and always requires a long clinical follow-up. Intolerance to aspirin is a factor of poor prognosis. A 15% failure rate was noted among patients intolerant to aspirin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1485748

Source DB:  PubMed          Journal:  Ann Otolaryngol Chir Cervicofac        ISSN: 0003-438X


  3 in total

1.  Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies.

Authors:  E Nucera; D Schiavino; A Milani; M Del Ninno; C Misuraca; A Buonomo; C D'Ambrosio; G Paludetti; G Patriarca
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Inflammatory rheumatism and nasal polyposis.

Authors:  M Laroche; E Ginesty; E Serrano; A Cantagrel; E Bon; L Moulinier; B Mazieres
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

3.  Smell Decline as a good Predictor of Sinonasal Polyposis Recurrence after Endoscopic Surgery.

Authors:  Mahdi Bakhshaee; Mohammad Reza Sharifian; Amir Hossain Ghazizadeh; Kianoosh Nahid; Karim Jalaeian Samani
Journal:  Iran J Otorhinolaryngol       Date:  2016-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.